Literature DB >> 27112370

A clinical practical approach to the surveillance definition of central line-associated bloodstream infection in cancer patients with mucosal barrier injury.

Anne-Marie Chaftari1, Mary Jordan2, Ray Hachem2, Zanaib Al Hamal2, Ying Jiang2, Ammar Yousif2, Kumait Garoge2, Poonam Deshmukh2, Issam Raad2.   

Abstract

BACKGROUND: The Centers for Disease Control and Prevention recently introduced the concept of mucosal barrier injury (MBI) in an attempt to recognize the possibility of a gastrointestinal source for certain bloodstream infections. This could underestimate the central venous catheter (CVC) as the source of central line-associated bloodstream infection (CLABSI) in cancer. The definition of catheter-related bloodstream infection (CRBSI) by the Infectious Diseases Society of America is a more specific and stringent definition that identifies the CVC as the source of infection. In our study, we compared the 2 definitions in cancer patients.
METHODS: We retrospectively reviewed 149 CLABSI cases that occurred at our center between January 2013 and March 2014 who had 2 simultaneously positive blood cultures drawn from the CVC and peripheral site or concurrent paired tip and blood cultures.
RESULTS: Of the 149 patients with CLABSI, only 70 (47%) had definite CRBSI. CRBSI was identified more commonly in non-MBI CLABSI cases than MBI CLABSI (69% vs 18%, P < .0001).
CONCLUSIONS: The CRBSI definition may be more accurate in identifying the catheter as the source of bloodstream infection in patients with MBI. Because CRBSI continues to occur in patients with MBI, we caution against excluding all MBI patients from CLABSI surveillance.
Copyright © 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLABSI; CRBSI; Central line–associated bloodstream infection; MBI; catheter-related bloodstream infection; mucosal barrier injury

Mesh:

Year:  2016        PMID: 27112370     DOI: 10.1016/j.ajic.2016.03.011

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

1.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

Review 2.  Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis.

Authors:  C E Dandoy; M I Ardura; G A Papanicolaou; J J Auletta
Journal:  Bone Marrow Transplant       Date:  2017-03-27       Impact factor: 5.174

3.  Indwelling time of peripherally inserted central catheters and incidence of bloodstream infections in haematology patients: a cohort study.

Authors:  M G Caris; N A de Jonge; H J Punt; D M Salet; V M T de Jong; B I Lissenberg-Witte; S Zweegman; C M J E Vandenbroucke-Grauls; M A van Agtmael; J J W M Janssen
Journal:  Antimicrob Resist Infect Control       Date:  2022-02-17       Impact factor: 4.887

4.  Impact of Catheter Management on Clinical Outcome in Adult Cancer Patients With Gram-Negative Bacteremia.

Authors:  Johny Fares; Melissa Khalil; Anne-Marie Chaftari; Ray Hachem; Ying Jiang; Hagop M Kantarjian; Issam I Raad
Journal:  Open Forum Infect Dis       Date:  2019-09-28       Impact factor: 3.835

5. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

6.  Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  Boris Böll; Enrico Schalk; Dieter Buchheidt; Justin Hasenkamp; Michael Kiehl; Til Ramon Kiderlen; Matthias Kochanek; Michael Koldehoff; Philippe Kostrewa; Annika Y Claßen; Sibylle C Mellinghoff; Bernd Metzner; Olaf Penack; Markus Ruhnke; Maria J G T Vehreschild; Florian Weissinger; Hans-Heinrich Wolf; Meinolf Karthaus; Marcus Hentrich
Journal:  Ann Hematol       Date:  2020-09-30       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.